Anaplastic lymphoma kinase (ALK)-tyrosine kinase inhibitors rarely elicit complete
responses in patients with advanced ALK-rearranged non-small cell lung cancer (NSCLC) …

Osimertinib, a third-generation EGFR TKI, is the standard therapy for previously untreated
EGFR-mutated non-small cell lung cancer patients following the landmark FLAURA study …

The continuing evolution of treatment options in thoracic oncology requires the pathologist to
regularly update diagnostic algorithms for management of tumor samples. It is essential to …

The past decades witnessed the clinical employment of targeted therapies including but not
limited to tyrosine kinase inhibitors (TKIs) that restrain a broad variety of pro-tumorigenic …

Gefitinib is one of the most extensively utilized epidermal growth factor receptor-tyrosine
kinase inhibitors (EGFR-TKIs) for treating advanced lung adenocarcinoma (LUAD) patients …

Abstract Introduction MET exon 14 (METex14) skipping is a rare oncogenic driver in non–
small-cell lung cancer (NSCLC) for which targeted therapy with MET tyrosine kinase …

With its high incidence and mortality rates, cancer is one of the largest health problems
worldwide. Investigating various cancer treatment options has been the focus of many …

Lung cancer has been the leading cause of cancer-related deaths worldwide for decades.
Despite the increasing understanding of the underlying disease mechanisms, the prognosis …

Purpose: Efficacy of MEK inhibitors in KRAS+ NSCLC may differ based on specific KRAS
mutations and comutations. Our hypothesis was that docetaxel and trametinib would …

Overall survival in metastatic lung cancer has been dramatically improved with the use of
small molecule kinase inhibitors (SMKIs). Quantification of SMKI in cerebrospinal fluid (CSF) …